IASLC World Conference on Lung Cancer (WCLC) - Korea会刊咨询

购买须知:
1. 展商名录/电子会刊将在 1-2个工作日 内以 电子邮件形式 发送至 申请人邮箱 ,请注意查收(如未收到请查看垃圾邮箱或 联系 13732395222)
2. 在线展商名录/电子会刊仅支持浏览, 不发邮件 , 不支持复制 文字等内容
3. 购买页面有标注"含电话、邮箱"的为含联系方式的名录,未标即不含联系方式
展会基本信息
展商行业
Core Therapeutic Areas
Non-Small Cell Lung Cancer (NSCLC): Covers first-line treatment for squamous/non-squamous NSCLC, exploring the application of combination immunotherapy in patients with brain metastases and in the perioperative setting.
Small Cell Lung Cancer (SCLC): Presents treatment advancements for extensive-stage SCLC, including combination regimens of immunotherapy and targeted therapy.
Breakthroughs in Innovative Therapies
Immunotherapy: Updated clinical data on PD-1/PD-L1 inhibitors (, Hansizhuang®, HLX43) and bispecific antibody therapies (, Ivonescimab).
Targeted Therapy: Latest research progress on EGFR mutations (, Aiduotinib) and ALK alterations (, Cadonilimab).
Research on Special Populations
Patients with Brain Metastases: Comparative efficacy of targeted drugs in NSCLC with brain metastases (, Aiduotinib vs. Osimertinib).
Perioperative Management: Potential applications of immunotherapy before and after lung cancer surgery.
Academic Exchange Sessions
The conference features multiple modules, including:
Early Lung Cancer Screening: New technologies such as Low-Dose CT (LDCT) screening.
Advanced-Stage Treatment: Clinical progress of Antibody-Drug Conjugate (ADC) drugs and bispecific antibody therapies.
Special Populations: Treatment protocols for specific subgroups such as pediatric and elderly patients.


